Protagenic Therapeutics, Inc.\new Proceeds from Issuance of Warrants
Protagenic Therapeutics, Inc.\new (PTIX) reported Proceeds from Issuance of Warrants of $4.30 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-08-14
- Protagenic Therapeutics, Inc.\new proceeds from issuance of warrants for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from issuance of warrants for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from issuance of warrants for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from issuance of warrants for the quarter ending 2025-06-30 was $4.30M.
- Protagenic Therapeutics, Inc.\new proceeds from issuance of warrants for fiscal 2026 was $4.30M.
- Protagenic Therapeutics, Inc.\new proceeds from issuance of warrants for fiscal 2024 was $1.96M.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $4.30M 10-K · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $4.30M 10-Q · filed 2026-03-09 | $4.40M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-QT 3 month · filed 2025-11-26 | $4.30M 10-Q · filed 2025-11-26 | $4.40M derived: sum of 3 quarters · filed 2025-11-26 | $6.00M derived: sum of 4 quarters · filed 2025-11-26 |
| 2025-06-30 | $4.30M 10-QT · filed 2025-09-10 | $4.40M derived: sum of 2 quarters · filed 2025-09-10 | $6.00M derived: sum of 3 quarters · filed 2025-09-10 | $6.32M derived: sum of 4 quarters · filed 2025-09-10 |
| 2025-03-31 | $102.52K 10-Q · filed 2025-05-13 | $1.70M derived: sum of 2 quarters · filed 2025-05-13 | $2.02M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2024-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.92M derived: sum of 2 quarters · filed 2025-03-31 | $1.96M 10-K · filed 2025-03-31 | |
| 2024-09-30 | $316.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $361.49K 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $44.53K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |